Sofinnova Partners has closed its second crossover fund at €725 million (about $815 million), targeting roughly 15 late-stage life sciences companies. The fund is described as designed to bridge the financing gap for businesses moving from advanced clinical development toward commercialization. The announcement follows Sofinnova’s emphasis on supporting Europe’s bigger platform and commercialization-heavy biotechs. For portfolio companies, the new pool is positioned to reduce dependence on incremental venture rounds as trials mature and regulatory milestones approach. The closing also signals continued investor appetite for late-stage risk in the region, even as biotech financing cycles remain uneven.
Get the Daily Brief